Azoren

Azoren Adverse Reactions

olmesartan + amlodipine

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Full Prescribing Info
Adverse Reactions
Azoren: The most commonly reported adverse reactions during treatment with Azoren are peripheral oedema (11.3%), headache (5.3%) and dizziness (4.5%).
Adverse reactions from Azoren in clinical trials, post-authorisation safety studies and spontaneous reporting are summarised in the table as follows as well as adverse reactions from the individual components olmesartan medoxomil and amlodipine based on the known safety profile of these substances.
The following terminologies have been used in order to classify the occurrence of adverse reactions: Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000); Not known (cannot be estimated from the available data). (See table.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers. Single cases of extrapyramidal syndrome have been reported in patients treated with amlodipine.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in